It's The Journey, Inc. – Trademark Portfolio
Entity Type: 03
It's The Journey, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 5 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include DO THE 2, IT'S THE JOURNEY, GEORGIA ALLIANCE FOR BREAST CANCER, and GEORGIA 2-DAY WALK FOR BREAST CANCER. The owner is based in Atlanta, GA.
270 Carpenter Drive
Suite 515
Atlanta, GA 30328
Showing of trademarks Trademarks
Trademark Classifications
It's The Journey, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does It's The Journey, Inc. have?
It's The Journey, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 cancelled.
What trademark classes does It's The Journey, Inc. file in?
It's The Journey, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 35 (Advertising & Business). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are It's The Journey, Inc.'s most well-known trademarks?
It's The Journey, Inc.'s registered trademark portfolio includes well-known marks such as DO THE 2, IT'S THE JOURNEY, GEORGIA ALLIANCE FOR BREAST CANCER, and GEORGIA 2-DAY WALK FOR BREAST CANCER. These are among 4 currently registered trademarks in the portfolio.
What is It's The Journey, Inc.'s trademark registration success rate?
It's The Journey, Inc. has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.